| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1005281046 |
| P356 | DOI | 10.1007/S40291-016-0201-8 |
| P698 | PubMed publication ID | 27139908 |
| P2093 | author name string | Kim Moran-Jones | |
| P2860 | cites work | Use of a novel 3D culture model to elucidate the role of mesothelial cells, fibroblasts and extra-cellular matrices on adhesion and invasion of ovarian cancer cells to the omentum | Q80423904 |
| Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor-neutralizing monoclonal antibody, in a first-in-human study of patients with advanced solid tumors | Q82478744 | ||
| Increased circulating hepatocyte growth factor (HGF): a marker of epithelial ovarian cancer and an indicator of poor prognosis | Q83340733 | ||
| Gene amplification and protein overexpression of MET are common events in ovarian clear-cell adenocarcinoma: their roles in tumor progression and prognostication of the patient | Q83818621 | ||
| Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752 | Q24541450 | ||
| Origin and molecular pathogenesis of ovarian high-grade serous carcinoma | Q26852698 | ||
| Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma | Q27851979 | ||
| Major partial response to crizotinib, a dual MET/ALK inhibitor, in a squamous cell lung (SCC) carcinoma patient with de novo c-MET amplification in the absence of ALK rearrangement | Q27852650 | ||
| Integrated genomic analyses of ovarian carcinoma | Q27860518 | ||
| Cancer statistics, 2015 | Q27860576 | ||
| Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene | Q28202069 | ||
| Invasive growth: a MET-driven genetic programme for cancer and stem cells | Q28253680 | ||
| The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data | Q28266682 | ||
| Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal | Q28288215 | ||
| Hepatocyte growth factor-induced Ras activation requires ERM proteins linked to both CD44v6 and F-actin | Q28574426 | ||
| Comparison of c-met expression in ovarian epithelial tumors and normal epithelia of the female reproductive tract by quantitative laser scan microscopy | Q30646151 | ||
| Phase 1 dose-escalation trial evaluating the combination of the selective MET (mesenchymal-epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib | Q33161299 | ||
| Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome | Q33359495 | ||
| A phase I dose-escalation study of Tivantinib (ARQ 197) in adult patients with metastatic solid tumors | Q33397502 | ||
| A phase I dose escalation study of oral c-MET inhibitor tivantinib (ARQ 197) in combination with gemcitabine in patients with solid tumors | Q33414632 | ||
| Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study | Q33416122 | ||
| A first-in-human study of AMG 208, an oral MET inhibitor, in adult patients with advanced solid tumors | Q33424270 | ||
| Structure, tissue-specific expression, and transforming activity of the mouse met protooncogene | Q33696499 | ||
| Effective inhibition of c-MET-mediated signaling, growth and migration of ovarian cancer cells is influenced by the ovarian tissue microenvironment | Q33794185 | ||
| Phase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and multiple myeloma | Q33918113 | ||
| Ovarian cancer development and metastasis | Q34086819 | ||
| The target therapy of ovarian clear cell carcinoma | Q34274069 | ||
| Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET. | Q34335483 | ||
| Met is the most frequently amplified gene in endometriosis-associated ovarian clear cell adenocarcinoma and correlates with worsened prognosis | Q34613189 | ||
| Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer | Q35010777 | ||
| Expression and significance of CD44, CD47 and c-met in ovarian clear cell carcinoma | Q35139055 | ||
| Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer—Shifting the paradigm | Q35140600 | ||
| Assessment of hepatocyte growth factor in ovarian cancer mortality | Q35156876 | ||
| c-Met activation through a novel pathway involving osteopontin mediates oncogenesis by the transcription factor LSF | Q35242044 | ||
| MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib | Q35666332 | ||
| Hepatocyte growth factor (HGF) autocrine activation predicts sensitivity to MET inhibition in glioblastoma | Q35673676 | ||
| A phase II evaluation of AMG 102 (rilotumumab) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study | Q35747034 | ||
| CD44 is required for two consecutive steps in HGF/c-Met signaling. | Q35805198 | ||
| A clinical protocol to inhibit the HGF/c-Met pathway for malignant mesothelioma with an intrapleural injection of adenoviruses expressing the NK4 gene. | Q35855798 | ||
| Biomarker analyses from a placebo-controlled phase II study evaluating erlotinib±onartuzumab in advanced non-small cell lung cancer: MET expression levels are predictive of patient benefit | Q35858331 | ||
| A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth | Q35952832 | ||
| MET in gastric carcinomas: comparison between protein expression and gene copy number and impact on clinical outcome | Q36089948 | ||
| Extended progression-free survival in two patients with alveolar soft part sarcoma exposed to tivantinib | Q36925182 | ||
| MET Expression and Amplification in Patients with Localized Gastric Cancer | Q36949256 | ||
| Expression and mutational analysis of MET in human solid cancers | Q36975055 | ||
| MET amplification as a potential therapeutic target in gastric cancer. | Q36984821 | ||
| Ligand‐independent activation of MET through IGF‐1/IGF‐1R signaling | Q37018397 | ||
| FISH and immunohistochemical status of the hepatocyte growth factor receptor (c-Met) in 184 invasive breast tumors | Q37208761 | ||
| INC280, an orally available small molecule inhibitor of c-MET, reduces migration and adhesion in ovarian cancer cell models | Q37502372 | ||
| The TPR-MET oncogenic rearrangement is present and expressed in human gastric carcinoma and precursor lesions | Q37525133 | ||
| HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma | Q37632192 | ||
| Recurrent epithelial ovarian cancer: an update on treatment | Q38115551 | ||
| Developing biomarkers to predict benefit from HGF/MET pathway inhibitors | Q38150768 | ||
| The Met receptor tyrosine kinase: a key player in oncogenesis and drug resistance | Q38175267 | ||
| Patient-centric trials for therapeutic development in precision oncology. | Q38607709 | ||
| MET overexpression and amplification define a distinct molecular subgroup for targeted therapies in gastric cancer | Q38832652 | ||
| Hepatocyte growth factor secreted by ovarian cancer cells stimulates peritoneal implantation via the mesothelial-mesenchymal transition of the peritoneum. | Q38838337 | ||
| HGF as a circulating biomarker of onartuzumab treatment in patients with advanced solid tumors. | Q39443947 | ||
| Ischemic time impacts biological integrity of phospho-proteins in PI3K/Akt, Erk/MAPK, and p38 MAPK signaling networks | Q39510967 | ||
| IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer | Q39587868 | ||
| HGF/c-Met pathway has a prominent role in mediating antiapoptotic signals through AKT in epithelial ovarian carcinoma. | Q39675475 | ||
| Effect of a c-Met-specific, ATP-competitive small-molecule inhibitor SU11274 on human ovarian carcinoma cell growth, motility, and invasion | Q40049847 | ||
| Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary | Q40301883 | ||
| Hepatocyte growth factor (HGF) in ovarian epithelial tumour fluids stimulates the migration of ovarian carcinoma cells. | Q40925421 | ||
| Activated ras and ret oncogenes induce over-expression of c-met (hepatocyte growth factor receptor) in human thyroid epithelial cells | Q41109580 | ||
| Expression of the Met/HGF receptor in normal and neoplastic human tissues | Q41658755 | ||
| Developmental and Hormonal Regulation of Hepatocyte Growth Factor Expression and Action in the Bovine Ovarian Follicle1 | Q42460298 | ||
| Expression and action of hepatocyte growth factor in human and bovine normal ovarian surface epithelium and ovarian cancer | Q42483953 | ||
| Scatter factor/hepatocyte growth factor and its receptor, the c-met tyrosine kinase, can mediate a signal exchange between mesenchyme and epithelia during mouse development | Q42770153 | ||
| Modulation of hepatocyte growth factor gene expression by estrogen in mouse ovary | Q42834247 | ||
| A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2. | Q43062314 | ||
| Prognostic Value and Clinical Pathology of MACC-1 and c-MET Expression in Gastric Carcinoma | Q43418210 | ||
| Increased hepatocyte growth factor in serum in acute graft-versus-host disease | Q43710391 | ||
| EGF and HGF levels are increased during active HBV infection and enhance survival signaling through extracellular matrix interactions in primary human hepatocytes | Q44199432 | ||
| The effect of hepatocyte growth factor on the initial stages of mouse follicle development. | Q44409045 | ||
| Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer | Q44461877 | ||
| Microenvironment-derived HGF overcomes genetically determined sensitivity to anti-MET drugs. | Q44843363 | ||
| Mesenchymal-epithelial interactions in the ovarian follicle involve keratinocyte and hepatocyte growth factor production by thecal cells and their action on granulosa cells | Q44962794 | ||
| Molecular cloning of a new transforming gene from a chemically transformed human cell line. | Q45345810 | ||
| A novel activating function of c-Src and Stat3 on HGF transcription in mammary carcinoma cells | Q45345816 | ||
| Dualistic classification of epithelial ovarian cancer: surgical and survival outcomes in a large retrospective series. | Q45906655 | ||
| Phase I dose-escalation study of onartuzumab as a single agent and in combination with bevacizumab in patients with advanced solid malignancies | Q46081857 | ||
| Stability of phosphoprotein as a biological marker of tumor signaling | Q46549087 | ||
| MET overexpression assessed by new interpretation method predicts gene amplification and poor survival in advanced gastric carcinomas | Q46799794 | ||
| FGFR2, HER2 and cMet in gastric adenocarcinoma: detection, prognostic significance and assessment of downstream pathway activation | Q46815880 | ||
| The impact of delay in cryo-fixation on biomarkers of Src tyrosine kinase activity in human breast and bladder cancers | Q46971533 | ||
| Serum Interleukin‐6, Interleukin‐8, Hepatocyte Growth Factor, and Nitric Oxide Changes during Thoracic Surgery | Q47804587 | ||
| Overexpression of the Met/HGF receptor in ovarian cancer. | Q48079353 | ||
| New insights into ovarian cancer pathology | Q53143668 | ||
| Ovarian cancer ascites enhance the migration of patient-derived peritoneal mesothelial cells via cMet pathway through HGF-dependent and -independent mechanisms | Q53668906 | ||
| Immunohistochemical application of a highly sensitive and specific murine monoclonal antibody recognising the extracellular domain of the human hepatocyte growth factor receptor (MET). | Q53878549 | ||
| Expression profiles of HER2, EGFR, MET and FGFR2 in a large cohort of patients with gastric adenocarcinoma | Q54218339 | ||
| A phase II trial of a selective c-Met inhibitor tivantinib (ARQ 197) monotherapy as a second- or third-line therapy in the patients with metastatic gastric cancer | Q54390371 | ||
| Analysis of 1,115 patients tested for MET amplification and therapy response in the MD Anderson Phase I Clinic. | Q55070567 | ||
| Phase I Trial of a Selective c-MET Inhibitor ARQ 197 Incorporating Proof of Mechanism Pharmacodynamic Studies | Q62664175 | ||
| c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion | Q64377234 | ||
| Hepatocyte growth factor (HGF) receptor expression is inducible and is part of the delayed-early response to HGF | Q72403509 | ||
| Coexpression of hepatocyte growth factor-Met: an early step in ovarian carcinogenesis? | Q73787127 | ||
| Stromal-epithelial interactions in the progression of ovarian cancer: influence and source of tumor stromal cells | Q73812342 | ||
| Autocrine interactions of keratinocyte growth factor, hepatocyte growth factor, and kit-ligand in the regulation of normal ovarian surface epithelial cells | Q73941835 | ||
| Expression of the c-Met in advanced epithelial ovarian cancer and its prognostic significance | Q80366266 | ||
| P433 | issue | 3 | |
| P304 | page(s) | 199-212 | |
| P577 | publication date | 2016-04-30 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Molecular Diagnosis and Therapy | Q15758832 |
| P1476 | title | The Therapeutic Potential of Targeting the HGF/cMET Axis in Ovarian Cancer | |
| P478 | volume | 20 |
| Q33792661 | CAF-derived HGF promotes cell proliferation and drug resistance by up-regulating the c-Met/PI3K/Akt and GRP78 signalling in ovarian cancer cells | cites work | P2860 |
Search more.